Sterling Biotech
Sterling Biotech, headquartered in India, is a prominent player in the pharmaceutical and biotechnology industry, specialising in the production of high-quality pharmaceutical excipients and active pharmaceutical ingredients (APIs). Founded in 1995, the company has established a strong presence in both domestic and international markets, with significant operations across Asia, Europe, and the Americas. Renowned for its innovative approach, Sterling Biotech offers a diverse range of products, including starches, cellulose derivatives, and other excipients that enhance drug formulation. The company’s commitment to quality and sustainability has positioned it as a trusted partner for pharmaceutical manufacturers worldwide. With a focus on research and development, Sterling Biotech continues to achieve notable milestones, reinforcing its reputation as a leader in the biopharmaceutical sector.
DitchCarbon Score
How does Sterling Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sterling Biotech's score of 38 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sterling Biotech, headquartered in India, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Zydus Lifesciences Limited, from which it inherits emissions data and climate commitments. As of now, there are no documented reduction targets or climate pledges directly associated with Sterling Biotech. The emissions data and climate initiatives are cascaded from Zydus Lifesciences Limited, which is at a cascade level of 2 in the corporate family relationship. This means that any climate commitments or emissions performance metrics would be reflective of Zydus Lifesciences' broader sustainability strategies rather than specific actions taken by Sterling Biotech itself. In the absence of specific emissions figures or reduction targets, it is important to note that the company is part of an industry increasingly focused on sustainability and reducing carbon footprints. As such, Sterling Biotech may align with the climate initiatives and targets set forth by its parent company, Zydus Lifesciences, which may include participation in frameworks like the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). However, without specific data or commitments from Sterling Biotech, a detailed assessment of its carbon emissions and climate commitments remains unavailable.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Scope 1 | 92,070,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 168,794,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | 0,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sterling Biotech is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
